When reading various comments and initiatives on important issues for the development and placing on the market of medical devices, I am concerned about what seems to me to be an apparent confusion on topics such as clinical evaluation, risk management and state of the art of medical devices, with a separation of activities only for specific processes, that the benefit/risk determination is part of the risk management process or that the analysis of the current state of generally recognized knowledge/state of the art is only necessary for the clinical evaluation) which does not seem to make sense to me. Here are some initial thoughts for my (and possibly your) consideration:

For a variety of reasons that I won’t go into in this post (but may expand on in the future), the two basic aspects that define whether a medical device can be placed and maintained on the market are:

  • The device must be safe and effective
  • The device must not compromise the health or safety of the patient, user, or others

For the above two aspects to be true, it is also necessary that:

  • The potential risks must be compatible with a high degree of health and safety protection, given the current generally recognized state of knowledge
  • The potential risks associated with the use of the device must be acceptable when balanced against the expected clinical benefits that the device provides to the patient (seen in another way, the clinical benefits must “outweigh” the potential risks)